Das Blutungsrisiko unter Antidepressiva verstehen und einschätzen

Zusammenfassung

Antidepressiva, insbesondere die selektiven Serotoninwiederaufnahmehemmer (SSRI), sind die meistverordnete psychopharmakologische Arzneistoffgruppe, weshalb eine genaue Kenntnis der zu erwartenden unerwünschten Arzneimittelwirkungen unabdingbar ist. Das erhöhte Risiko für Blutungsereignisse ist vor allem bei Patienten, die mit SSRI behandelt werden, gut belegt. Mit wenigen Ausnahmen können jedoch auch die anderen antidepressiven Arzneistoffgruppen Einfluss auf die Blutgerinnung nehmen und somit das Blutungsrisiko erhöhen. In der nachfolgenden Übersichtsarbeit wird das thrombozytäre Serotoninsystem vorgestellt und die Angriffspunkte der unterschiedlichen Antidepressiva erläutert. Anschließend wird die zur Verfügung stehende Literatur zu Blutungen unter den jeweiligen Antidepressivaklassen bzw. einzelnen Substanzen vorgestellt, wobei hier nach Möglichkeit jeweils Daten aus Meta-Analysen herangezogen werden. Neben dem allgemeinen Blutungsrisiko werden zudem einzelne Blutungsentitäten betrachtet, wie gastrointestinale und Hirnblutungen. Zuletzt werden die Auswirkungen von anderen blutgerinnungsfördernden Arzneistoffen (Nichtsteroidale Antirheumatika, Thrombozytenaggregationshemmer und Antikoagulanzien) in Kombination mit Antidepressiva diskutiert. Mit dem vorgestellten Wissen soll es Behandlern in Zukunft leichter fallen Entscheidungen hinsichtlich einer geeigneten antidepressiven Pharmakotherapie anhand der patientenindividuellen Risikokonstellation zu treffen.

Abstract

Antidepressants, in particular selective serotonin reuptake inhibitors (SSRIs), are the most commonly prescribed psychopharmacological drug group. Thus, a precise knowledge of the expected adverse drug reactions is indispensable. The increased risk of bleeding events is well documented, especially in patients treated with SSRIs. However, many other antidepressant drug groups have also been implicated in increasing the risk of bleeding. In the following review, the thrombocytic serotonin system and the respective targets of the different antidepressants are explained. Subsequently, the available literature on bleeding under the respective antidepressant classes or individual substances is presented, using data from metaanalyses whenever possible. In addition to the risk of bleeding in general, individual bleeding entities are also considered, such as gastrointestinal and cerebral hemorrhages. Finally, the effects of other drugs that increase the risk of bleeding (i. e., nonsteroidal anti-inflammatory drugs, platelet aggregation inhibitors and anticoagulants) in combination with antidepressant drugs are discussed. The information presented here is meant to guide practitioner’s decision making regarding an appropriate antidepressant pharmacotherapy based on the patient’s individual risk constellation.

Schlüsselwörter

Antidepressiva - Gerinnung - Blutung - Thrombozyten - Serotonin

Keywords

antidepressant drugs - hemostasis - bleeding - thrombocyte - serotonin

Publikationsverlauf

Artikel online veröffentlicht:
03. April 2025

• Literatur

• 1 Seifert J, Bleich S, Seifert R. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizithyperaktivitätssyndrom. In: Arzneiverordnungs-Report 2022. Springer; 2023: 451-495
• 2 Noordam R, Aarts N, Verhamme KM. et al. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. Eur J Clin Pharmacol 2015; 71: 369-375
• 3 Lako IM, Taxis K, Bruggeman R. et al. The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. Eur Psychiatry 2012; 27: 240-244
• 4 Jelkmann W. Allgemeine Eigeschaften des Blutes. In: Brandes R, Lang F, Schmidt RF. Hrsg. Physiologie des Menschen mit Pathophysiologie. 32. Aufl. Springer; Berlin, Heidelberg: 2019: 285-305
• 5 Gamoh S, Hisa H, Yamamoto R. 5-hydroxytryptamine receptors as targets for drug therapies of vascular-related diseases. Biol Pharm Bull 2013; 36: 1410-1415
• 6 Cloutier N, Allaeys I, Marcoux G. et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proceedings of the National Academy of Sciences 2018; 115: E1550-E1559
• 7 Li N, Wallén NH, Ladjevardi M. et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-523
• 8 Duerschmied D, Bode C. [The role of serotonin in haemostasis]. Hamostaseologie 2009; 29: 356-359
• 9 Kawano Y, Obana M, Nagata M. et al. The antiplatelet effect of mirtazapine is mediated by co-blocking 5-HT(2 A) and α(2)-adrenergic receptors on platelets: An in vitro human plasma-based study. Eur J Pharmacol 2022; 917: 174640
• 10 Youdim MBH. Platelet monoamine oxidase B: Use and misuse. Experientia 1988; 44: 137-141
• 11 Meijer WEE, Heerdink ER, Nolen WA. et al. Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants. Arch Internal Med 2004; 164: 2367-2370
• 12 Castro VM, Gallagher PJ, Clements CC. et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open 2012; 2: e000544
• 13 Lewis JD, Strom BL, Localio AR. et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17: 328-335
• 14 Wang YP, Chen YT, Tsai CF. et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014; 171: 54-61
• 15 Renoux C, Vahey S, Dell’Aniello S. et al. Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage. JAMA Neurol 2017; 74: 173-180
• 16 Wu CS, Wang SC, Cheng YC. et al. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 2011; 168: 511-521
• 17 Stórustovu S, Sánchez C, Pörzgen P. et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004; 142: 172-180
• 18 Bayoumi AB, Ikizgul O, Karaali CN. et al. Antidepressants in Spine Surgery: A Systematic Review to Determine Benefits and Risks. Asian Spine J 2019; 13: 1036-1046
• 19 Cheng YL, Hu HY, Lin XH. et al. Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in Taiwan. Medicine (Baltimore) 2015; 94: e2022
• 20 Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG. et al. Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors. Neuropsychopharmacology 2001; 25: 871-880
• 21 Yuet WC, Derasari D, Sivoravong J. et al. Selective Serotonin Reuptake Inhibitor Use and Risk of Gastrointestinal and Intracranial Bleeding. J Am Osteopath Assoc 2019; 119: 102-111
• 22 Eslami Shahrbabki M, Eslami Shahrbabaki A. Sertraline-related bleeding tendency: could it be dose-dependent?. Iran J Psychiatry Behav Sci 2014; 8: 81-83
• 23 Nelson JC. Tricyclic and tetracyclic drugs. The American Psychiatric Association Publishing Textbook of Psychopharmacology 5th ed. Arlington, VA: American Psychiatric Association Publishing; 2017: 305-334
• 24 BindungDB. Zugriff am 09. Februar 2023 unter: https://www.bindingdb.org/rwd/bind/index.jsp
• 25 PDSP Ki Database. Zugriff am 09. Februar 2023 unter: https://pdsp.unc.edu/databases/kidb.php
• 26 Anglin R, Yuan Y, Moayyedi P. et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 811-819
• 27 Jiang HY, Chen HZ, Hu XJ. et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 42-50.e43
• 28 Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. Ann Pharmacother 2019; 53: 186-194
• 29 Laporte S, Chapelle C, Caillet P. et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res 2017; 118: 19-32
• 30 Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004; 65: 1642-1653
• 31 Trajkova S, dʼErrico A, Soffietti R. et al. Use of Antidepressants and Risk of Incident Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology 2019; 53: 142-151
• 32 Singh I, Achuthan S, Chakrabarti A. et al. Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis. Pharmacoepidemiol Drug Saf 2015; 24: 237-245
• 33 Roose SP, Rutherford BR. Selective Serotonin Reuptake Inhibitors and Operative Bleeding Risk: A Review of the Literature. J Clin Psychopharmacol 2016; 36: 704-709
• 34 Zafirova Z, Vázquez-Narváez KG, Borunda D. Preoperative Management of Medications. Anesthesiol Clin 2018; 36: 663-675
• 35 Jiang HY, Xu LL, Li YC. et al. Antidepressant use during pregnancy and risk of postpartum hemorrhage: A systematic review and meta-analysis. J Psychiatr Res 2016; 83: 160-167
• 36 Marcinkowska M, Kubacka M, Zagorska A. et al. Exploring the antiplatelet activity of serotonin 5-HT(2 A) receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif- as potential therapeutic agents in the prevention of cardiovascular diseases. Biomed Pharmacother 2022; 145: 112424
• 37 Arnold DM, Nazi I, Warkentin TE. et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013; 27: 137-145
• 38 Stuhec M, Alisky J, Malesic I. Mirtazapine associated with drug-related thrombocytopenia: a case report. J Clin Psychopharmacol 2014; 34: 662-664
• 39 Na K-S, Jung H-Y, Cho S-J. et al. Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis. J Affect Disord 2018; 225: 221-226
• 40 de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109
• 41 Coupland C, Dhiman P, Morriss R. et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Bmj 2011; 343: d4551
• 42 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin, Germany: Springer; 2021
• 43 Vardar MK, Kovalak EE. Abnormal Uterine Bleeding Associated with Bupropion: A Case Report. Bagcilar Med Bul 2022; 7: 288-290
• 44 Frankhauser P, Grimmer Y, Bugert P. et al. Characterization of the neuronal dopamine transporter DAT in human blood platelets. Neurosci Lett 2006; 399: 197-201
• 45 Schedel A, Schloss P, Klüter H. et al. The dopamine agonism on ADP-stimulated platelets is mediated through D2-like but not D1-like dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 431-439
• 46 Dhawan BN, Mathur GB, Rajvanshi VS. Effects of some centrally acting drugs on blood coagulation. Jpn J Pharmacol 1968; 18: 445-453
• 47 Juang H-T, Chen P-C, Chien K-L. Using antidepressants and the risk of stroke recurrence: report from a national representative cohort study. BMC Neurology 2015; 15: 86
• 48 Sheikh Rezaei S, Mittlböck M, Reichardt B. et al. SSRI co-medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010–2015. Int J Geriatr Psychiatry 2019; 34: 1194-1199
• 49 Nochaiwong S, Ruengorn C, Awiphan R. et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med 2022; 54: 80-97
• 50 Shao IY, Claxton JNS, Lutsey PL. et al. Association of Type of Antidepressant Initiation with Bleeding Risk in Atrial Fibrillation Patients Taking Oral Anticoagulants. Drugs – Real World Outcomes 2021; 8: 383-391
• 51 Alam SM, Qasswal M, Ahsan MJ. et al. Selective serotonin reuptake inhibitors increase risk of upper gastrointestinal bleeding when used with NSAIDs: a systemic review and meta-analysis. Sci Rep 2022; 12: 14452
• 52 de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803
• 53 Hou PC, Lin FJ, Lin SY. et al. Risk of Intracranial Hemorrhage With Concomitant Use of Antidepressants and Nonsteroidal Antiinflammatory Drugs: A Nested Case-Control Study. Ann Pharmacother 2021; 55: 941-948
• 54 Shin JY, Park MJ, Lee SH. et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal antiinflammatory drugs: nationwide propensity score matched study. BMJ 2015; 351: h3517
• 55 Nelva A, Guy C, Tardy-Poncet B. et al. Hemorrhagic syndromes related to selective serotonin reuptake inhibitor (SSRI) antidepressants. Seven case reports and review of the literature. Rev Med Interne 2000; 21: 152-160
• 56 Akca B, Siller-Matula J. Plättchenfunktionstestung: Erwartung und Realität. Journal für Kardiologie-Austrian. Journal of Cardiology 2013; 20: 160-167
• 57 Calatzis A. Blutungszeit, Thrombelastographie und PFA-100. In: Hämostaseologie. Springer; 2010: 839-843